Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia

被引：0
|
作者：
Verbalis, JG
Bisaha, JG
Smith, N
机构：
[1] Yamanouchi Pharma Amer Inc, Paramus, NJ USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3346
引用
收藏
页码：723 / 723
页数：1
相关论文
共 50 条
  • [1] Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S27 - S27
  • [2] Novel vasopressin V1A and V2 antagonist (Conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure
    Verbalis, JG
    Ghali, JK
    Gross, P
    Long, WA
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S120 - S120
  • [3] Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [4] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [5] Conivaptan hydrochloride.: Treatment of heart failure, Treatment of hyponatremia, Vasopressin V1a/V2 antagonist.
    Norman, P
    Leeson, PA
    Rabasseda, X
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2000, 25 (11) : 1121 - 1130
  • [6] A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Wada, Koh-ichi
    Matsuyawa, Utane
    Fujimori, Akira
    Arai, Yukinori
    Sudoh, Katsumi
    Sasamata, Masao
    Miyata, Keiji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (01) : 91 - 95
  • [7] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, C
    Bichet, D
    Udelson, JE
    Ghazzi, MM
    Selaru, P
    Chartier, K
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [8] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, CA
    Ghazzi, MM
    Selaru, P
    Bichet, DG
    Chartier, KK
    Udelson, JE
    CIRCULATION, 2000, 102 (18) : 535 - 535
  • [9] Conivaptan:: A dual vasopressin receptor V1a/V2 antagonist (vol 25, pg 261, 2007)
    不详
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (04): : 397 - 397
  • [10] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
12345